Showing results (321-330 of 427) with videos related to

Sort By:
Pageof 43
Leukemia Research|June 28, 2011
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinibRoberto Latagliata, Massimo Breccia, Fausto Castagnetti, et al.
Hematological Oncology|January 1, 2020
Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatmentRoberto Latagliata, Pasquale Niscola, Luana Fianchi, et al.
Annals of Hematology|May 3, 2019
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practiceGiovanni Caocci, Olga Mulas, Elisabetta Abruzzese, et al.
British Journal of Haematology|January 11, 2026
Risk factors and reasons for switching from front-line therapy in the Italian chronic myeloid leukaemia network: A cohort studyMassimo Breccia, Valentina Giai, Tiziana Rosso, et al.
Hemasphere|March 25, 2025
Patient and physician perceptions regarding treatment expectations and symptomatology in polycythemia vera: Insights from the Landmark 2.0 global health surveyClaire N Harrison, David M Ross, Laura Maria Fogliatto, et al.
American Journal of Hematology|January 11, 2016
Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patientsAlessandro Andriani, Roberto Latagliata, Barbara Anaclerico, et al.
Cancer Medicine|May 26, 2017
Role of treatment on the development of secondary malignancies in patients with essential thrombocythemiaCristina Santoro, Isabella Sperduti, Roberto Latagliata, et al.
Hematological Oncology|May 18, 2017
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent studyFrancesca Palandri, Mario Tiribelli, Giulia Benevolo, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 21, 2020
Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center CohortSofia Chiatamone Ranieri, Maria Antonietta Arleo, Stefania Trasarti, et al.
Cell Death & Disease|June 30, 2022
Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemiaMohammad Houshmand, Nicoletta Vitale, Francesca Orso, et al.
Pageof 43